Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 13/20 | 0.42 |
| ▸ | JAK3 | P52333 | 13/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19413023 | 0.84 | JAK2 (0.43) | SMPD3JAK2JAK3PIK3CGKCNQ3 | |
| SCHEMBL15306539 | 0.81 | PIK3CG (0.54) | SMPD3PIK3CGKCNQ3KCNQ2AXL | |
| SCHEMBL14752169 | 0.81 | PIK3CG (0.42) | SMPD3JAK2JAK3PIK3CGKCNQ3 | |
| SCHEMBL5741027 | 0.80 | SMPD3 (0.50) | SMPD3JAK2JAK3PIK3CGAXL | |
| SCHEMBL19916808 | 0.79 | JAK2 (0.42) | SMPD3JAK2JAK3PIK3CGKCNQ3 | |
| SCHEMBL19413053 | 0.79 | JAK2 (0.42) | SMPD3JAK2JAK3PIK3CGKCNQ3 | |
| SCHEMBL19916752 | 0.77 | JAK2 (0.41) | SMPD3JAK2JAK3PIK3CG | |
| SCHEMBL25024705 | 0.77 | PIK3CG (0.57) | SMPD3JAK2JAK3PIK3CGKCNQ3 | |
| SCHEMBL15308491 | 0.77 | PIK3CG (0.49) | SMPD3JAK2JAK3PIK3CGAXL | |
| SCHEMBL14672718 | 0.76 | JAK2 (0.37) | SMPD3JAK2JAK3PIK3CGKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2021-02-18 | — | — | US | disclosed |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | ASTRAZENECA AB (SE) | 2020-12-08 | — | — | US | disclosed |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2020-09-24 | — | — | US | disclosed |
| US-10759806-B2 | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10675286-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190202835-A1 | ISOTOPOLOGUES OF ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS AND USES THEREOF AS PI3K KINASE INHIBITORS | TWELVE THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10329299-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-9255108-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150105385-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-8940742-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2013-10-10 | — | — | US | disclosed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675286-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885JAK2 51/4885JAK3 171/4885 |
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PIK3CD, PIK3CG, PIK3CA | SMPD3 305/4885JAK2 306/4885JAK3 213/4885 |
| US-20190202835-A1 | ISOTOPOLOGUES OF ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS AND USES THEREOF AS PI3K KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3CB | SMPD3 1947/4885JAK2 27/4885JAK3 40/4885 |
| US-20120122888-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNJ2 | SMPD3 1749/4885JAK2 1625/4885JAK3 3825/4885 |
| US-20150105385-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885JAK2 51/4885JAK3 171/4885 |
| US-10329299-B2 | Heterocyclic compounds and uses thereof | PIK3CA, AKT1, AKT2 | SMPD3 853/4885JAK2 58/4885JAK3 270/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885JAK2 51/4885JAK3 171/4885 |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | PIK3CD, PIK3CG, PIK3CA | SMPD3 305/4885JAK2 306/4885JAK3 213/4885 |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885JAK2 51/4885JAK3 171/4885 |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885JAK2 51/4885JAK3 171/4885 |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PI4KA, PIK3CD, PI4KB | SMPD3 492/4885JAK2 517/4885JAK3 293/4885 |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885JAK2 51/4885JAK3 171/4885 |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885JAK2 51/4885JAK3 171/4885 |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885JAK2 51/4885JAK3 171/4885 |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885JAK2 51/4885JAK3 171/4885 |
| US-10759806-B2 | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors | PIK3CA, PIK3CD, PIK3CB | SMPD3 1947/4885JAK2 27/4885JAK3 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.